Nivolumab and Relatlimab-rmbw

FDA label information for this drug is available at DailyMed.

Use in Cancer

Nivolumab and relatlimab-rmbw is approved to treat:

• Melanoma that is metastatic or cannot be removed by surgery. It is used in adults and children aged 12 years and older.

Nivolumab and relatlimab-rmbw is a combination form of nivolumab and relatlimab. This form may work better than either drug alone. For more information about nivolumab that may apply to this combination drug, see the Drug Information Summary for Nivolumab.

Nivolumab and relatlimab-rmbw is also being studied in the treatment of other types of cancer.

More About Nivolumab and Relatlimab-rmbw

Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

More About Nivolumab and Relatlimab-rmbw – A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects

Targeted Cancer Therapies

Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3

Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Clinical Trials Accepting Patients

Find Clinical Trials for Nivolumab/relatlimab-rmbw – Check for trials from NCI’s list of cancer clinical trials now accepting patients.